Nonetheless, additional evidence indicates that in specific tumor contexts such as in renal cancer HIF-1α may also play tumor suppressive functions [17], thus indicating that the clinical application of pre-clinical studies with HIF inhibitors should be carefully planned. Here, HIF1A is linked to renal carcinoma.